menu

Autosomal Dominant Hypocalcemia Type 1 Market

Schedule Call

Autosomal Dominant Hypocalcemia Type 1 Market

Autosomal Dominant Hypocalcemia Type 1 Market by Treatment (Calcium Analog, Vitamin Analogs), End User (Hospitals, Clinics) – Global Outlook & Forecast 2023-2031

GR - 315764 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: April 14, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


Autosomal Dominant Hypocalcemia Type 1 Market Scope

Report Attribute

Details

CAGR

2.7%

Base Year For Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Treatment, End User, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global autosomal dominant hypocalcemia type 1 is expected to register a revenue CAGR of 2.7% from 2023 to 2031. 

Autosomal Dominant Hypocalcemia Type 1 Market Fundamentals     

Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder characterized by abnormally low levels of calcium in the blood. This condition is caused by mutations in the CASR gene, which is responsible for developing the calcium-sensing receptor protein. The calcium-sensing receptor has a crucial role in regulating the amount of calcium in the blood. When calcium levels are low, the receptor stimulates the release of a parathyroid hormone, which helps increase calcium levels. However, in people with ADH1, mutations in the CASR gene causes the calcium-sensing receptor to be less responsive to changes in calcium levels, leading to low levels of calcium in the blood. Symptoms of ADH1 may include muscle cramps, spasms, twitches, numbness and tingling in the hands and feet, and even seizures.

In some cases, patients with ADH1 can also suffer from low levels of magnesium in the blood, thus causing additional symptoms such as fatigue, weakness, and abnormal heart rhythms. The traditional treatment for ADH1 involves taking calcium and vitamin D supplements to raise calcium levels in the blood. Treatment options for ADH1 may include medications, such as diazoxide or octreotide, to help regulate insulin secretion and dietary modifications to maintain stable blood sugar levels. In some cases, surgical intervention, such as a partial or total pancreatectomy, can also be considered. In some cases, medications such as acidimetric may also be used to help increase the sensitivity of the calcium-sensing receptor. Regular monitoring of calcium and magnesium levels is important to ensure effective treatment and prevent complications such as kidney stones and bone loss.

Autosomal Dominant Hypocalcemia Type 1 Market Dynamics

Increasing awareness of ADH1 among healthcare professionals and people has led to earlier diagnosis and treatment of the disease. Since ADH1 is a rare disease, it evolves diagnostic methods, enabling early detection of symptomatic and non-symptomatic patients. The unmet medical need due to the well-defined treatment for DH1 is driving the development of new treatments for the disease. Additionally, regulatory bodies such as the FDA (Food and Drug Administration) and EMA (The European Medicines Agency) are also supporting the development of treatments for rare diseases.

Moreover, some opportunities can bolster the market revenue growth during the forecast period, such as advances in research, specifically in understanding the genetic basis of ADH1, which can lead to the development of new treatments for the condition. This can include novel pharmacological or gene therapies addressing the underlying genetic defects. Moreover, there is a growing rate of patient awareness through advocacy and support groups. The rising influence of social media is also playing a key role in attracting attention to this disease group. Market players, drug developers, research institutions, healthcare facilities, and patient groups are also frequently collaborating, augmenting the overall awareness about the disease and the current treatment options. Collaboration between researchers, healthcare professionals, patient advocacy groups, and regulators can also help to address the challenges facing the ADH1 market. Since ADH1 is a rare disease, the treatments for such a medical condition are eligible for orphan drug designation. This can provide financial incentives, including tax credits and reduced regulatory fees, to encourage the development of treatments for the condition. Advances in precision medicine can enable the development of targeted treatments for ADH1 based on an individual's specific genetic defect. This could improve treatment outcomes and reduce the risk of adverse effects.

Currently, there are several challenges and constraints faced by the global autosomal dominant hypocalcemia type 1 market that can impact the development and commercialization of treatments for such a rare medical condition. Although awareness of ADH1 is growing, many healthcare professionals still poorly understand the condition. This can lead to delays in diagnosis and treatment and limit the market for ADH1 treatments. The pathophysiology of ADH1 is complex and not entirely understood yet. This is creating challenges in the way of developing effective treatments for the condition. Limited clinical data are available on the safety and efficacy of treatments for ADH1, making it difficult for regulators to approve new treatments and physicians to prescribe them confidently. Developing treatments for rare diseases like ADH1 can be expensive due to the small patient population and the need to conduct extensive clinical trials to demonstrate safety and efficacy. 

Autosomal Dominant Hypocalcemia Type 1 Market Ecosystem

The global autosomal dominant hypocalcemia type 1 market is analyzed from three perspectives: treatment, end user, and region.

Autosomal Dominant Hypocalcemia Type 1 Market by Treatment

[86585]

Based on the treatment, the global autosomal dominant hypocalcemia type 1 market is segmented into calcium analogs and vitamin analogs. 

The calcium analog segment accounts for a prominent revenue share in the global autosomal dominant hypocalcemia type 1 market. Calcium analogs, such as calcitriol and calcium supplements, are the mainstay in managing autosomal dominant hypocalcemia type 1. They are effective at managing the symptoms of the disease and are widely available and accessible. As of the current scenario, there are limited treatment options available for ADH1, which means that calcium analogs are often the only sustainable option for patients with the condition. Calcium analogs are inexpensive and cost-effective, making them an attractive option for healthcare providers. There is a significant body of clinical evidence supporting the use of calcium analogs in the treatment of ADH1. This evidence has demonstrated their safety and efficacy, contributing to their widespread adoption of the standard of care. Calcium analogs have minimal side effects, which makes them well-tolerated by patients with ADH1. This can improve patient compliance and quality of life.

According to several studies, vitamin D insufficiency can also reduce glucose metabolism and insulin production, exacerbating hypoglycemia episodes in people with ADH1 and increasing the demand for vitamin analogs.  Vitamin D has also been implicated in regulating insulin sensitivity, which may enhance insulin receptor expression and function. Furthermore, some research has indicated that vitamin D supplementation has a beneficial effect on glucose metabolism and insulin sensitivity in individuals with diabetes, which can potentially extend to ADH1 as well. People with ADH1 have low levels of calcium in their blood, which can cause symptoms such as muscle cramps, seizures, and fatigue. Vitamin D2 or D3 (ergocalciferol or cholecalciferol, respectively) or vitamin D metabolites [calcitriol or 1,25-(OH)2 vitamin D or 1 alpha-OH vitamin D (not available in the US)] are frequently required for people with autosomal dominant hypocalcemia type 1. However, due to less evidence, there is a need for research to fully understand the potential role of vitamin D in the growth of ADH1. 

Autosomal Dominant Hypocalcemia Type 1 Market by End User

Based on the end user, the global autosomal dominant hypocalcemia type 1 market is segmented into hospitals, clinics, and others.

Since hospitals have a large patient pool, it is considered the primary healthcare facility, accounting for the largest revenue share in the global autosomal dominant hypocalcemia type 1 market.  Additionally, as the number of instances of hypocalcemia rises, so does the demand for rapid diagnosis and treatments. Additionally, hospitals provide well-skilled healthcare practitioners with novel diagnostic and management systems. Furthermore, the presence of reimbursement policies and high patient satisfaction rates further fuels the revenue growth of this segment, thereby propelling the overall market growth. 

Autosomal Dominant Hypocalcemia Type 1 Market by Region

Based on the region, the global autosomal dominant hypocalcemia type 1 market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The market for autosomal dominant hypocalcemia type 1 treatment in North America is relatively small due to the rare nature of the condition. In North America, the treatment of ADH1 is typically managed by a multidisciplinary team of healthcare professionals, including endocrinologists, geneticists, and other specialists. Due to the rarity of ADH1, there may be limited commercial interest in developing specialized treatments for this condition.

Similarly, Europe's autosomal dominant hypocalcemia type 1 market is expected to grow slowly. Europe has a well-established healthcare infrastructure with advanced medical facilities, trained healthcare professionals, and sophisticated medical technologies. Additionally, Europe is also home to many of the leading research institutions across the globe. Europe has an aging population, and older adults are more likely to develop hypocalcemia, thus contributing to the growing demand for diagnosis and management drugs for treating autosomal dominant hypocalcemia type 1 in the region.

Autosomal Dominant Hypocalcemia Type 1 Market Competitive Landscape

New product approvals and launches, promising product pipelines, and mergers and acquisitions can provide ample growth opportunities for the companies operating in the market. The prominent players operating in the global autosomal dominant hypocalcemia type 1 market are:

Autosomal Dominant Hypocalcemia Type 1 Market Strategic Development

  • In December 2022, BridgeBio Pharma began its pivotal Phase 3 randomized study of Encaleret in individuals with autosomal dominant hypocalcemia type 1 (CALIBRATE). The CALIBRATE research integrates comments from worldwide regulatory agencies and patients, with a primary composite endpoint of blood and urine calcium concentrations within normal limits in persons treated with Encaleret vs. SoC. SoC for ADH1 is extra-dietary calcium and active vitamin D analog supplementation. While SoC may alleviate acute hypocalcemia symptoms, it may also worsen high urine calcium levels, leading to renal complications.

Frequently Asked Questions About This Report

Autosomal dominant hypocalcemia (ADH) type 1 is caused by heterozygous activating mutations in the CASR, which increase the sensitivity of the CASR to extracellular ionized calcium.

The global autosomal dominant hypocalcemia type 1 market is expected to register a revenue CAGR of 2.7% from 2023 to 2031.

The calcium analogs segment accounts for a prominent revenue share in the global autosomal dominant hypocalcemia type 1 market with the largest revenue share.

Limited knowledge about the disease and lack of standard treatment are some of the restraints in the global autosomal dominant hypocalcemia type 1 market revenue growth.

Some market players operating in the global autosomal dominant hypocalcemia type 1 market are BridgeBio Inc., Shire (Takeda), and F. Hoffmann-La Roche AG.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022)
    3. Regulatory Landscape
    4. Reimbursement Scenario
    5. Epidemiology and Patient Population Forecast to 2031
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints
    3. Opportunities
  5. GLOBAL AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 MARKET- ANALYSIS & FORECAST, BY TREATMENT
    1. Calcium Analogs
    2. Vitamin Analogs
  6. GLOBAL AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 MARKET- ANALYSIS & FORECAST, BY END USER
    1. Hospitals 
    2. Clinics
    3. Others
  7. GLOBAL AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 MARKET- ANALYSIS & FORECAST, BY REGION
    1. North America Autosomal Dominant Hypocalcemia Type 1 Market
      1. North America Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
      2. North America Autosomal Dominant Hypocalcemia Type 1 Market, by End User
      3. North America Autosomal Dominant Hypocalcemia Type 1 Market, by Country
        1. U.S.
          1. U.S. Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. U.S. Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        2. Canada
          1. Canada Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Canada Autosomal Dominant Hypocalcemia Type 1 Market, by End User
    2. Europe Autosomal Dominant Hypocalcemia Type 1 Market
      1. Europe Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
      2. Europe Autosomal Dominant Hypocalcemia Type 1 Market, by End User
      3. Europe Autosomal Dominant Hypocalcemia Type 1 Market, by Country/Region
        1.  Germany
          1. Germany Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Germany Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        2. U.K.
          1. U.K. Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. U.K. Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        3. France
          1. France Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. France Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        4. Spain
          1. Spain Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Spain Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        5. Italy
          1. Italy Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Italy Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        6. Rest of Europe
          1. Rest of Europe Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Rest of Europe Autosomal Dominant Hypocalcemia Type 1 Market, by End User
    3. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market
      1. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
      2. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by End User
      3. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by Country/Region
        1. China
          1. China Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. China Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        2. Japan
          1. Japan Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Japan Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        3. India
          1. India Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. India Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        4. South Korea
          1. South Korea Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. South Korea Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        5. Australia
          1. Australia Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Australia Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        6. Rest of Asia Pacific 
          1. Rest of Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Rest of Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by End User
    4. Latin America Autosomal Dominant Hypocalcemia Type 1 Market
      1. Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
      2. Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by End User
      3. Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by Country/ Region
        1. Brazil
          1. Brazil Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Brazil Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        2. Mexico
          1. Mexico Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Mexico Autosomal Dominant Hypocalcemia Type 1 Market, by End User 
        3. Argentina
          1. Argentina Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment 
          2. Argentina Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        4. Rest of Latin America
          1. Rest of Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Rest of Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by End User 
    5. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market
      1. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
      2. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, by End User
      3. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. GCC Countries Autosomal Dominant Hypocalcemia Type 1 Market, by End User
        2. South Africa
          1. South Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. South Africa Autosomal Dominant Hypocalcemia Type 1 Market, by End User 
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment
          2. Rest of Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, by End User
  8. COMPANY PROFILES         
    1. BridgeBio Inc.
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Shire (Takeda)
    3. Abbott Laboratories Inc.
    4. F. Hoffmann-La Roche AG

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  2. Global Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  3. Global Autosomal Dominant Hypocalcemia Type 1 Market, by Region, 2021-2031 (US$ Million) 
  4. North America Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  5. North America Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  6. North America Autosomal Dominant Hypocalcemia Type 1 Market, by Country, 2021-2031 (US$ Million) 
  7. U.S. Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  8. U.S. Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  9. Canada Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  10. Canada Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  11. Europe Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  12. Europe Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  13. Europe Autosomal Dominant Hypocalcemia Type 1 Market, by Country/ Region, 2021-2031 (US$ Million) 
  14. Germany Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  15. Germany Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  16. U.K. Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  17. U.K. Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  18. France Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  19. France Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  20. Italy Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  21. Italy Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  22. Spain Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  23. Spain Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  24. Rest of Europe Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  25. Rest of Europe Autosomal Dominant Hypocalcemia Type 1 Market, by aEnd User, 2021-2031 (US$ Million)
  26. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  27. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  28. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by Country/ Region, 2021-2031 (US$ Million) 
  29. China Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  30. China Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  31. Japan Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  32. Japan Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  33. India Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  34. India Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  35. South Korea Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  36. South Korea Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  37. Australia Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  38. Australia Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  39. Rest of Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  40. Rest of Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021-2031 (US$ Million)
  41. Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  42. Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  43. Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by Country/ Region, 2021–2031 (US$ Million)
  44. Brazil Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  45. Brazil Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  46. Mexico Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  47. Mexico Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  48. Argentina Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  49. Argentina Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  50. Rest of Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  51. Rest of Latin America Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  52. Middle East and Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  53. Middle East and Africa Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  54. Middle East and Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Country/ Region, 2021–2031 (US$ Million)
  55. GCC Countries Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  56. GCC Countries Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  57. South Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  58. South Africa Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 
  59. Rest of Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, by Treatment, 2021-2031 (US$ Million)
  60. Rest of Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, by End User, 2021–2031 (US$ Million) 

List of Figures

 

  1. Autosomal Dominant Hypocalcemia Type 1 Market Ecosystem  
  2. Snapshot of Global Autosomal Dominant Hypocalcemia Type 1 Market, 2021 & 2031
  3. Snapshot of Global Autosomal Dominant Hypocalcemia Type 1 Market, by Region, 2021 & 2031
  4. Global Autosomal Dominant Hypocalcemia Type 1 Market: COVID-19 Pandemic Impact Assessment 
  5. Global Autosomal Dominant Hypocalcemia Type 1 Market: Key Players & Competitive Positioning (2022) 
  6. Autosomal Dominant Hypocalcemia Type 1: Market Dynamics 
  7. Global Autosomal Dominant Hypocalcemia Type 1 Market for Calcium Analog, 2021-2031 (US$ Million)
  8. Global Autosomal Dominant Hypocalcemia Type 1 Market for Vitamin Analogs, 2021-2031 (US$ Million)
  9. Global Autosomal Dominant Hypocalcemia Type 1 Market for Hospitals, 2021-2031 (US$ Million)
  10. Global Autosomal Dominant Hypocalcemia Type 1 Market for Clinics, 2021-2031 (US$ Million)
  11. Global Autosomal Dominant Hypocalcemia Type 1 Market for Others, 2021-2031 (US$ Million)
  12. North America Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  13. U.S. Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  14. Canada Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  15. Europe Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  16. Germany Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  17. U.K. Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  18. France Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  19. Italy Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  20. Spain Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  21. Rest of Europe Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  22. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  23. China Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  24. Japan Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  25. India Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  26. South Korea Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  27. Australia Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  28. Rest of Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  29. Latin America Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  30. Brazil Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  31. Mexico Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  32. Argentina Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million)
  33. Rest of Latin America Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million)
  34. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  35. GCC Countries Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  36. South Africa Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  37. Rest of Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market, 2021-2031 (US$ Million) 
  38. BridgeBio Inc. Revenue from 2019 Onwards (US$ Million)
  39. Shire (Takeda) Revenue from 2019 Onwards (US$ Million)
  40. Abbott Laboratories Inc. Revenue from 2019 Onwards (US$ Million)
  41. F. Hoffmann-La Roche AG Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Autosomal Dominant Hypocalcemia Type 1 Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Autosomal Dominant Hypocalcemia Type 1 Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports